Skip to main content
SpringerLink
Log in

Prostate cancer in 2014

The year chemotherapy finally gets some respect!

  • Year in Review
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

The past 5 years have seen some of the most significant changes in the way we view and treat prostate cancer. 2014 continues in the same spirit and will be remembered as a landmark year for practice changing studies reporting their results in surgery, chemotherapy and novel medical therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. de Bono, J. S., Logothetis, C. J., & Molina, A. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    Article  CAS  Google Scholar 

  2. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

    Article  CAS  Google Scholar 

  3. Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).

    Article  Google Scholar 

  4. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

    Article  CAS  Google Scholar 

  5. Rathkopf, D. E. et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.02.056.

  6. Ryan, C. J. et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy [abstract 7530]. Ann. Oncol. 25 (Suppl. 4), iv255–iv279 (2014).

    Article  Google Scholar 

  7. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).

    Article  Google Scholar 

  8. Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial [abstract]. J. Clin. Oncol. 32 (Suppl.), LBA2 (2014).

    Article  Google Scholar 

  9. Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med. 370, 932–942 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Hospitalier de l'Université de Montréal, University of Montreal, CHUM Pavillon R, 900 rue St Denis, Montreal, H2X 0A9, QC, Canada

    Fred Saad

Authors
  1. Fred Saad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fred Saad.

Ethics declarations

Competing interests

The author declares that he acts as a consultant and has received research funding from Abbvie, Amgen, Astellas, Janssen, Millennium, and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saad, F. The year chemotherapy finally gets some respect!. Nat Rev Urol 12, 71–72 (2015). https://doi.org/10.1038/nrurol.2014.362

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.362

  • Springer Nature Limited

This article is cited by

Search

Navigation